

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450

				<u> </u>	
Γ	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/842,466	04/26/2001	· Hiroyasu Kokubo	35576/233803	8005
	826 7	7590 07/21/2003			
	ALSTON & I			EXAMI	NER
	2111111111111	IERICA PLAZA RYON STREET, SUITI	E 4000	SHEIKH, HUMERA N	
	CHARLOTTE	, NC 28280-4000	000	ART UNIT	PAPER NUMBER
				1615	
				DATE MAILED: 07/21/2003	13

Please find below and/or attached an Office communication concerning this application or proceeding.

•	•				
	Application No.	Applicant(s)			
	09/842,466	KOKUBO ET AL.			
Office Action Summary	Examiner	Art Unit			
·	Humera N Sheikh	1615			
The MAILING DATE of this communical Period for Reply	tion appears on the cover sheet wi	th the correspondence address			
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICA - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this communi - If the period for reply specified above is less than thirty (30) d - If NO period for reply is specified above, the maximum statute - Failure to reply within the set or extended period for reply will - Any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b). Status	ATION. 37 CFR 1.136(a). In no event, however, may a recation. days, a reply within the statutory minimum of thirty only period will apply and will expire SIX (6) MON I, by statute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed	on 02 June 2003 (paper no. 12) .				
)☐ This action is non-final.				
3) Since this application is in condition for closed in accordance with the practice					
Disposition of Claims					
4)⊠ Claim(s) <u>6-20</u> is/are pending in the ap	•				
4a) Of the above claim(s) is/are	withdrawn from consideration.				
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>6-20</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction	n and/or election requirement				
Application Papers					
9) The specification is objected to by the E	xaminer.				
10)☐ The drawing(s) filed on is/are: a)	☐ accepted or b)☐ objected to by the	ne Examiner.			
Applicant may not request that any object					
11)☐ The proposed drawing correction filed o	n is: a)□ approved b)□ di	isapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action. :					
12)☐ The oath or declaration is objected to by	the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120	<u> </u>				
13) Acknowledgment is made of a claim for	r foreign priority under 35 U.S.C. §	} 119(a)-(d) or (f).			
a)⊠ All b)⊡ Some * c)⊡ None of:		•			
 Certified copies of the priority do 	cuments have been received:	•			
2. Certified copies of the priority do	cuments have been received in Ap	oplication No			
	the priority documents have been onal Bureau (PCT Rule 17.2(a)). or a list of the certified copies not re-	-			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign langu	age provisional application has be	een received.			
Attachment(s)	domestic priority under 35 U.S.C.	33 120 anu/01 121.			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO- 3) Information Disclosure Statement(s) (PTO-1449) Pape	-948) 5) Notice of Ir	Summary (PTO-413) Paper No(s). <u>1</u> 9 . Informal Patent Application (PTO-152)			
<u> </u>					

DETAILED ACTION

Status of the Application

Receipt of the request for extension of time (1 month) and the Amendment, both filed 06/02/03 is acknowledged.

The 35 U.S.C. 112 second paragraph rejections have been withdrawn.

Claims 6-20 are pending. Claims 6, 7, 10 and 15-17 have been amended. Claim 1 has been cancelled. Claims 6-20 are rejected.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 6-8, 10 and 15-17 are rejected under 35 U.S.C. 102(b) as being anticipated by Berta (US Pat. No. 4,820,524).

Berta discloses a solid, multi-colored medicament preparation having a gelatinous coating, wherein the coating layer provides two or more different colors (see reference col. 4, lines 39-42).

The medicament may be in the form of a caplet and contains a layer of gelatin as a single coating on the caplet core.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 9, 11-14 and 18-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berta (US Pat. No. 4,820,524).

As discussed above, Berta teaches a solid, multi-colored medicament preparation having a gelatinous coating, wherein the coating layer provides two or more different colors (see reference col. 4, lines 39-42).

Application/Control Number: 09/842,466

Art Unit: 1615

Berta also teaches a method for coating the solid cores, such as caplets, to produce simulated, capsule-like medicaments. Berta teaches that one objective of the invention is to provide a simulated, capsule-like medicament having a gelatinous coating capable of being provided in two or more colors. Another objective is to provide a heavy layer of gelatin as a *single* coating to cover imperfections inherent on the caplet core (col. 4, lines 12-56). Suitable coatings to be used are gelatinous materials, such as methyl cellulose, calcium alginate and gelatin. Additional ingredients include plasticizers, preservatives, coloring agents and opacifying agents (col. 8, lines 20-47).

Berta teaches a solid, multi-colored medicament wherein colorings can be added to the coatings to produce *opaque* or *transparent* colors, such as red, white, pink, green, reddish brown, blue, yellow and black, for example. Colored medicaments are necessary to give a specialty product a distinctive appearance. To form white medicaments or an opaque colored coating, titanium dioxide is often added to the gelatin (col. 9, lines 1-7).

Berta teaches that the solid, multi-colored medicament preparation additionally comprises various coating patterns (see Figs. 8 a-d and col. 5, lines 28-29). Berta does not explicitly teach a logo, letters or a bar code on the medicament. However, the inclusion of logos, bar codes or letters, as instantly claimed does not make the invention patentable since variations in designs or patterns in solid medicament forms is commonly and routinely practiced in the pharmaceutical art.

Berta teaches a solid preparation comprising a gelatinous coating that provides two or more colors wherein the medicament is smooth, shiny, multi-colored and has various coating patterns. These medicaments are pleasing to the eye, are easier to swallow than prior medicaments and offer a distinctive appearance, as similarly desired by the applicant.

Response to Arguments

Applicant's arguments filed 06/02/03 have been fully considered but they are not persuasive.

The applicant argued over the 35 USC 102(b) rejection over Berta ('524) and the 35 USC 103(a) rejections of claims 9-14 and 18-20 stating, "Claim 10 is a solid preparation coated with a continuous film coating layer comprising at least one colorant. At least a portion of the film-coating layer is exposed to radiation under conditions to modify the color of the colorant so as to provide a coating layer with at least two different colors. The examiner indicated during the interview that Berta et al. do not teach or suggest the use of ultraviolet radiation to effect a color change in a tablet."

These arguments have been fully considered, but were not found to be persuasive. A product is being claimed in the instant invention, not the process by which it was prepared. It is the product that must be patentable. More particularly, the claims are drawn to a product that has 2 distinct colors as essentially taught by the Berta reference (see col. 4, lines 39-56 where there is the teaching of a gelatinous

coating capable of being provided in two or more colors. The gelatin coating can be provided as a single coating). Because of this teaching, the claims are fully met.

Conclusion -

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Humera N. Sheikh whose telephone number is (703)

Application/Control Number: 09/842,466

Art Unit: 1615

Page 7

308-4429. The examiner can normally be reached on Monday through Friday from

7:00A.M. to 4:30P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Thurman Page, can be reached on (703) 308-2927. The fax phone number

for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.

hns July 18, 2003

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY OF TER 1600